Dynavax Technologies | DVAX - Interest Expense On Debt



Dynavax Technologies reported $1.64M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Adma Biologics USD 1.83M 1.05M Jun/2025
Amgen USD 694M 29M Jun/2025
AstraZeneca 303M 126M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Dynavax Technologies USD 1.64M 51K Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
Glaxosmithkline 184M 5.95M Jun/2025
Merck USD 305M 8M Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 289M 19M Jun/2025
Pfizer USD 654M 0 Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sarepta Therapeutics USD 5.23M 725K Jun/2025
TG Therapeutics USD 6.72M 4.12M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025